Showing posts with label questor. Show all posts
Showing posts with label questor. Show all posts

Tuesday

Investing Online Tuesday Share Tips

Stock Market Investing - Tuesday Newspaper Share Tips

The Daily Telegraph

Questor - Share Tips

Speculative Buy Antisoma - Antisoma is a loss-making biotech, but it has lots going for it which make it more than a gamble. It is fully funded until mid-2011, has a number of potential treatments at a late stage in development and Novartis is on its side.

Buy International Ferro Metals and wait

Other comments

US credit shrinking at same rate as seen in Great Depression giving rising to fears of double-dip recession


The Times

Tempus - Share Tips


Avoid Helphire At 36½p, or 14 times earnings. - Recovery from recession, even if it slow, will provide relief for Helphire. But can Credit hire, the niche pioneered by Helphire still be considered a growth industry, given its greater take-up since the downturn in 2001, and the willingness of Acromas and others to find alternative means of settling claims.

Hold Antisoma - its appeal is that it has enough cash until 2011. At 28p the recent improved sentiment on US biotechs — usually a lead indicator for European counterparts — should support the shares.

Pass on International Ferro Metals at 58½p, or 10 times 2011 earnings, it is high enough for now.

Rumour of the day - Sprint Nextel Corp rose 10% to $4.16 on speculation it might be acquired by Deutsche Telekom, even though analysts say this would be difficult to pull off.

Deal of the day - Mark Dixon, founder and CEO of Regis, said after the market had closed that he was selling about 3% of the company to institutional investors in what will be seen by many as a sign that demand is picking up. This is about 10% of his stake.

Bet of the day - Debenhams figures come out this morning and are expected to show fall of about 5% in Q4 sales, despite the department store’s best efforts.

Tiddler to watch - Charlemagne Capital, a fund manager that specializes in emerging markets, rose 1½p to 16p after receiving a “buy” recommendation from UBS which set a target of 16½p for the stock. Assets under management rose by 28% in Q2 to $2.4 bn.


The Independent
Investment - Share Tips
Buy Sainsbury's
- Potential clouds could be Tesco pricing cuts and CEO Justin King jumping ship to M&S, although he has said he won't.

The shares have fallen slightly over the past year, but long-term Sainsbury's look in a good position to benefit from more spending by core customers after the recession.

Buy Velti - Velti was one of the first mobile advertising cos. to deliver marketing and technology for cos. such as Vodafone and Orange, Coca Cola and Honda. Advertisers are looking to find new ways of exploiting mobile phones and a 2010 PE of almost 6 times, Velti looks good value.

****

Related Posts

Sunday Newspaper Share Tips + Rod Huusinen Video

Sunday

Weekend Share Tips Aug 09

Online Investing - Weekend Newspaper Share Tips

SUNDAY SHARE TIPS

SUNDAY TELEGRAPH

Questor:

Buy Gulfsands Petroleum at 176p
Hold Mouchel at 186.5p
Take profits at ASOS at 345p


MAIL ON SUNDAY
Midas Share Tips


BG Group solid, reliable and should deliver for many more years
Accsys Technology can cash in fake hardwood
Andy Brough from Schroders, to add to his holding in Novae Group


SATURDAY SHARE TIPS
THE TIMES
Tempus:

Who will benefit from women's increasing financial power ? (HSBC, Standard Chartered, Prudential, Kingfisher, Cadbury, Unilever, Tesco, GlaxoSmithKline, Diageo)

Other comment:

FinnCap says Ffastfill is a logical target for Thomson Reuters or Fidessa

Bet of the day: Intercontinental Hotels

Tiddler to watch - Avacta

DAILY MAIL

Investment Extra:


Some ideas for your portfolio from Richard Buxton from Schroders (Tesco, Unilever, Burberry, Experian, BG Group)

Other comment:

Borders UK may be next high street casualty

Numis questions accounting policies at Brewin Dolphin

DAILY EXPRESS

Taking Stock:

Hold on for rise in biotechs (BTG, Vectura, Antisoma, GW Pharma, Abcam, Oxford Biomedica, Proximagen, Vernalis,)
Healthy forecast for Immupharma.

***
How to read Stock market charts